SUPERLUMINAL MEDICINES
Live / Applied — Third extension granted (statement of use) (as of 23 Feb 2026)
What this means for you
Not registered yet, but its 06 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98212701
- Mark type
- Stylized text
- Filed
- 06 Oct 2023
- Published for opposition
- 09 Jul 2024
- Attorney of record
- Gregory B. Coy
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical agents modulating high value protein targets such as G protein coupled receptors
- Class 042 — Scientific and technological services: Development of pharmaceutical preparations and medicines
Owner
- Superluminal Medicines, Inc., Boston, MA, US
- Superluminal Medicines, Inc., Boston, MA, US
Prosecution history
- 24 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 23 Feb 2026 — SOU EXTENSION 3 GRANTED
- 23 Feb 2026 — SOU EXTENSION 3 FILED
- 23 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 20 Jan 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 20 Jan 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 20 Jan 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Aug 2025 — SOU EXTENSION 2 GRANTED
- 29 Aug 2025 — SOU EXTENSION 2 FILED
- 29 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Mar 2025 — SOU EXTENSION 1 GRANTED
- 03 Mar 2025 — SOU EXTENSION 1 FILED